☆ 4.5 Letter

Ketamine and Esketamine augmentation for suicidal ideation: A randomized, double-blinded clinical trial

GENERAL HOSPITAL PSYCHIATRY (2021)

Journal

GENERAL HOSPITAL PSYCHIATRY

Volume 68, Issue -, Pages 97-99

Publisher

ELSEVIER SCIENCE INC

DOI: 10.1016/j.genhosppsych.2020.12.011

Keywords

Ketamine; Esketamine; Suicidal ideation; Suicide; Depression; Treatment-resistant depression

Categories

Psychiatry

Funding

Programa de Pesquisa para o SUS (PPSUS/BA) [003/2017]
Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior -Brazil (CAPES) [001]

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Clinical Neurology

Magnetoencephalography biomarkers of suicide attempt history and antidepressant response to ketamine in treatment-resistant major depression

Jessica R. Gilbert, Jessica L. Gerner, Courtney R. Burton, Allison C. Nugent, Carlos A. Zarate, Elizabeth D. Ballard

Summary: This study investigated the magnetoencephalographic (MEG) correlates of suicidal ideation (SI) and suicide attempt history in patients with treatment-resistant major depression (TRD), both at baseline and after subanesthetic-dose ketamine infusion. The findings showed that ketamine significantly reduced SI and depression in the sample. Following ketamine infusion, attempters showed improved accuracy on the task, while non-attempters showed reduced accuracy. SI was positively associated with gamma power in frontal and parietal cortices. In an extended amygdalahippocampal region, attempters differed significantly in their emotional reactivity to angry versus happy faces as indexed by theta power differences, regardless of drug. Ketamine also reduced the association between alpha power and SI for angry compared to happy faces in a fronto-insular/anterior cingulate region important for regulating sensory attentiveness.

JOURNAL OF AFFECTIVE DISORDERS (2022)

Add to Collection

Article Neurosciences

Ketamine as Add-On Treatment in Psychotic Treatment-Resistant Depression

Maria Galuszko-Wegielnik, Zuzanna Chmielewska, Katarzyna Jakuszkowiak-Wojten, Mariusz S. Wiglusz, Wieslaw J. Cubala

Summary: Psychotic treatment-resistant depression is a challenging manifestation of mood disorders in clinical settings, often underdiagnosed and undertreated. This study aimed to assess the usage of ketamine as an add-on treatment for major depressive disorder with psychotic features, and the results suggest its potential benefits for individuals with treatment-resistant depression.

BRAIN SCIENCES (2023)

Add to Collection

Article Clinical Neurology

Role of klotho on antidepressant and antisuicidal effects of low-dose ketamine infusion among patients with treatment-resistant depression and suicidal ideation

Mu-Hong Chen, Ya-Mei Bai, Hui-Ju Wu, Cheng-Ta Li, Wei-Chen Lin, Shih-Jen Tsai, Tung-Ping Su, Pei-Chi Tu

Summary: This study aimed to investigate the effect of low-dose ketamine infusion on klotho levels among patients with treatment-resistant depression (TRD). The results showed that although ketamine did not significantly increase klotho levels, patients in the ketamine group had higher levels of klotho at Day 3 postinfusion compared to patients in the midazolam group. However, no association was found between changes in klotho levels and changes in depressive and suicidal symptoms. Higher baseline klotho levels were associated with a poorer antidepressant effect of low-dose ketamine during postinfusion follow-up.

JOURNAL OF AFFECTIVE DISORDERS (2023)

Add to Collection

Review Clinical Neurology

Acute Effects of Intravenous Sub-Anesthetic Doses of Ketamine and Intranasal Inhaled Esketamine on Suicidal Ideation: A Systematic Review and Meta-Analysis

Cheng-Chuan Chen, Na Zhou, Na Hu, Jian-Guo Feng, Xiao-Bin Wang

Summary: This meta-analysis found that intravenous sub-anesthetic doses of ketamine and intranasal inhaled esketamine have significant anti-suicidal ideation effects. Specifically, ketamine produced a large anti-suicidal ideation effect within 4-6 hours and a medium-large effect within 24 hours. Esketamine, on the other hand, produced a small-medium anti-suicidal ideation effect within the 4-6 hours timeframe and the 24 hours.

NEUROPSYCHIATRIC DISEASE AND TREATMENT (2023)

Add to Collection

Article Chemistry, Medicinal

Efficacy of Ketamine with and without Lamotrigine in Treatment-Resistant Depression: A Preliminary Report

Boney Joseph, Nicolas A. Nunez, Simon Kung, Jennifer L. Vande Voort, Vanessa K. Pazdernik, Kathryn M. Schak, Stacey M. Boehm, Brooke Carpenter, Emily K. Johnson, Grigoriy Malyshev, Nathan Smits, Daniel O. Adewunmi, Sarah K. Brown, Balwinder Singh

Summary: This study investigates the response to serial ketamine/esketamine treatment among patients with treatment-resistant depression (TRD) with or without lamotrigine therapy. The results showed no significant differences in response or remission rates among patients on or not on lamotrigine during the ketamine/esketamine treatments.

PHARMACEUTICALS (2023)

Add to Collection

Article Clinical Neurology

The effectiveness of repeated intravenous ketamine on subjective and objective psychosocial function in patients with treatment-resistant depression and suicidal ideation

Yanling Zhou, Chengyu Wang, Xiaofeng Lan, Wei Zheng, Hanqiu Li, Ziyuan Chao, Roger S. McIntyre, Yuping Ning

Summary: This study found that ketamine has beneficial effects on functional outcomes in patients with treatment-resistant depression. Depressive symptoms severity and processing speed performance are significant mediators of improvements in objective and subjective functioning.

JOURNAL OF AFFECTIVE DISORDERS (2022)

Add to Collection

Article Psychiatry

Neurocognitive aspects of ketamine and esketamine on subjects with treatment-resistant depression: A comparative, randomized and double-blind study

Lucas Araujo-de-Freitas, Cassio Santos-Lima, Euclides Mendonca-Filho, Flavia Vieira, Ricardo J. A. F. Franca, Guilherme Magnavita, Tanise L. Cardoso, Fernanda S. Correia-Melo, Gustavo C. Leal, Ana Paula Jesus-Nunes, Breno Souza-Marques, Roberta Marback, Manuela Teles, Mariana V. F. Echegaray, Graziele Beanes, Livia N. F. Guerreiro-Costa, Rodrigo P. Mello, Thais Rabanea, Ana Cecilia Lucchese, Neander Abreu, Acioly L. T. Lacerda, Lucas C. Quarantini

Summary: The study aimed to evaluate cognition in TRD patients receiving ketamine or esketamine, finding no significant difference in cognitive effects between the two drugs except for minor variations. When combined as a group, ketamine and esketamine showed improved cognitive functions in areas such as memory and processing speed, with effects lasting up to 7 days.

PSYCHIATRY RESEARCH (2021)

Add to Collection

Article Psychiatry

Cortical inhibition function is associated with baseline suicidal symptoms and post-ketamine suicidal symptom reduction among patients with treatment-resistant depression and strong suicidal ideation

Mu-Hong Chen, Tung-Ping Su, Li-Fen Chen, Cheng-Ta Li, Hui-Ju Wu, Wei-Chen Lin, Shih-Jen Tsai, Ya-Mei Bai, Wei-Chung Mao, Pei-Chi Tu, Jia-Shyun Jeng, Wei -Chi Li

Summary: The study found that there are differences in cortical excitation and inhibition functions between patients with treatment-resistant depression and strong suicidal ideation and healthy controls. It is still unclear whether the cortical excitation and inhibition functions can be modulated by a 0.5 mg/kg ketamine infusion.

JOURNAL OF PSYCHIATRIC RESEARCH (2023)

Add to Collection

Article Clinical Neurology

Factors associated with transitioning from suicidal ideation to suicide attempt in the short-term: Two large cohorts of depressed outpatients

Alejandro Porras-Segovia, Benedicte Nobile, Emilie Olie, Elia Gourguechon-Buot, Enrique Baca Garcia, Philip Gorwood, Sofia Abascal-Peiro, Philippe Courtet

Summary: This study investigates the factors associated with transitioning from recent suicidal ideation to suicide attempts in depressed outpatients. The study followed up on depressed adult outpatients in France for six weeks. Logistic regressions were used to explore the differences between patients with suicidal ideation who attempted suicide and those who did not.

JOURNAL OF AFFECTIVE DISORDERS (2023)

Add to Collection

Review Pharmacology & Pharmacy

Ketamine and esketamine in suicidal thoughts and behaviors: a systematic review

Fabrice Jollant, Romain Colle, Thi Mai Loan Nguyen, Emmanuelle Corruble, Alain M. M. Gardier, Martin Walter, Mocrane Abbar, Gerd Wagner

Summary: This study reviewed the use of ketamine and esketamine for the treatment of suicidal ideas and acts. The results showed that intravenous racemic ketamine significantly reduced suicidal ideation within the first 72 hours, with minor and transient adverse events. In contrast, intranasal esketamine did not differ from placebo in large-scale studies. The study also highlighted limitations, clinical considerations, and opportunities for future research.

THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY (2023)

Add to Collection

Article Psychiatry

Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation

Roger S. McIntyre, Joshua D. Rosenblat, Charles B. Nemeroff, Gerard Sanacora, James W. Murrough, Michael Berk, Elisa Brietzke, Seetal Dodd, Philip Gorwood, Roger Ho, Dan Iosifescu, Carlos Lopez Jaramillo, Siegfried Kasper, Kevin Kratiuk, Jung Goo Lee, Yena Lee, Leanna M. W. Lui, Rodrigo B. Mansur, George Papakostas, Mehala Subramaniapillai, Michael Thase, Eduard Vieta, Allan H. Young, Carlos A. Zarate, Stephen Stahl

Summary: Replicated international studies have highlighted the human and societal costs of major depressive disorder, with monoamine-based antidepressants proving effective but many patients failing to fully recover. Ketamine and esketamine offer novel pharmacological treatments for treatment-resistant depression, but questions remain about their safety and effectiveness. International experts provide guidance on the use of these agents, while discussing areas of consensus and future research directions.

AMERICAN JOURNAL OF PSYCHIATRY (2021)

Add to Collection

Article Clinical Neurology

mTORC1 inhibitor effects on rapid ketamine-induced reductions in suicidal ideation in patients with treatment-resistant depression

Lynnette A. Averill, Christopher L. Averill, Ralitza Gueorguieva, Samar Fouda, Mohamed Sherif, Kyung-Heup Ahn, Mohini Ranganathan, Deepak Cyril D'Souza, Steven M. Southwick, Gerard Sanacora, Ronald S. Duman, John H. Krystal, Chadi G. Abdallah

Summary: Ketamine has demonstrated rapid and robust improvements in suicidal ideation, but the mechanism and trajectory of its effects are still not well understood.

JOURNAL OF AFFECTIVE DISORDERS (2022)

Add to Collection

Article Clinical Neurology

Patterns of use, clinical efficacy, safety and tolerability of Ketamine and Esketamine in treatment-resistant depression: Towards registry-based surveillance systems

Alvaro Lopez-Diaz, Luisa Rendon de Lope, Diego de la Vega Sanchez

Summary: More data on the long-term effects of Racemic Ketamine and Esketamine in TDR patients is needed, and the implementation of centralized registries for tracking their use in depression treatment could be crucial for assessing their efficacy and safety in real-world clinical practice. This paper outlines the emergence and rationale behind these registry-based surveillance systems.

JOURNAL OF AFFECTIVE DISORDERS (2022)

Add to Collection

Article Psychiatry

Ketamine study: Protocol for naturalistic prospective multicenter study on subcutaneous ketamine infusion in depressed patients with active suicidal ideation

Ana Paula Anzolin, Jeferson Ferraz Goularte, Jairo Vinicius Pinto, Paulo Belmonte-de-Abreu, Luciane Nascimento Cruz, Victor Hugo Schaly Cordova, Lucas Sueti Magalhaes, Adriane R. Rosa, Keila Maria Cereser, Marcia Kauer-Sant'Anna

Summary: This study aims to assess the control effect of ketamine on suicidal ideation and behavior in patients with depressive episodes, as well as its impact on psychopathology and inflammatory biomarkers.

FRONTIERS IN PSYCHIATRY (2023)

Add to Collection

Article Clinical Neurology

A Randomized, Double-Blind, Midazolam-Controlled Trial of Low-Dose Ketamine Infusion in Patients With Treatment-Resistant Depression and Prominent Suicidal Ideation

Tung-Ping Su, Cheng-Ta Li, Wei-Chen Lin, Hui-Ju Wu, Shih-Jen Tsai, Ya-Mei Bai, Wei-Chung Mao, Pei-Chi Tu, Li-Fen Chen, Wei-Chi Li, Mu-Hong Chen

Summary: This study suggests that low-dose ketamine infusion is a safe and effective treatment for patients with TRD and prominent suicidal ideation. The timing of ketamine administration, specifically the duration of the current depressive episode and the number of failed antidepressant trials, plays an important role in achieving therapeutic response.

INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2023)

Add to Collection

Review Psychiatry

Biomarkers of neuroprogression and late staging in bipolar disorder: A systematic review

Sonya Grewal, Stuart McKinlay, Flavio Kapczinski, Bianca Pfaffenseller, Bianca Wollenhaupt-Aguiar

Summary: This systematic review examines the biological markers associated with illness progression in bipolar disorder. It finds that increased ventricular size and reduction of grey matter volume are common brain changes associated with the progression of the disorder. In addition, peripheral inflammatory markers also play a role in this process.

AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY (2023)

Add to Collection

Article Public, Environmental & Occupational Health

Lifestyle Behaviors, Depression, and Anxiety Among Individuals Living in Canada During the COVID-19 Pandemic

Mario Simjanoski, Taiane de Azevedo Cardoso, Bianca Wollenhaupt-Aguiar, Bianca Pfaffenseller, Vicent Balanza-Martinez, Luciano Minuzzi, Flavio Kapczinski

Summary: This study investigated the association between lifestyle behaviors and symptoms of depression and anxiety during the COVID-19 pandemic in Canada. The results showed that unhealthy lifestyle behaviors were associated with depression and anxiety symptoms, emphasizing the importance of lifestyle medicine education and targeted interventions.

AMERICAN JOURNAL OF LIFESTYLE MEDICINE (2023)

Add to Collection

Article Psychiatry

The relationship between objective and subjective cognitive performance to clinical features in bipolar disorder: A 6 years follow-up study

Leticia Sanguinetti Czepielewski, Marcia Kaurer-Sant Anna, Flavio Kapczinski, Joana Bucker

EUROPEAN JOURNAL OF PSYCHIATRY (2023)

Add to Collection

Article Psychiatry

Childhood trauma, inflammatory biomarkers and the presence of a current depressive episode: Is there a relationship in subjects from a population study?

Leonardo Carvalho Oliveira, Natalia Wirowski, Pedro Borges de Souza, Andressa Schneider Lobato, Karen Jansen, Taiane de Azevedo Cardoso, Thaise Campos Mondin, Jean Pierre Oses, Flavio Kapczinski, Luciano Dias de Mattos Souza, Ricardo Azevedo da Silva, Fernanda Pedrotti Moreira

Summary: This study aims to compare the serum cytokine levels between controls, individuals with a current depressive episode (CDE) with childhood trauma and individuals with CDE without childhood trauma. The study found that individuals with CDE had elevated levels of certain cytokines compared to the control group, while other cytokines showed decreased levels. However, there was no significant difference in cytokine levels between individuals with CDE, with and without trauma. The findings suggest that monitoring cytokine levels may be beneficial in preventing the development of a CDE.

JOURNAL OF PSYCHIATRIC RESEARCH (2023)

Add to Collection

Article Psychiatry

Predictors of illicit substance abuse/dependence during young adulthood: A machine learning approach

Coral Rakovski, Pedro L. Ballester, Bruno Braga Montezano, Luciano Dias de Mattos Souza, Karen Jansen, Ricardo Azevedo da Silva, Thaise Campos Mondin, Fernanda Pedrotti Moreira, Raquel Brandini De Boni, Benicio N. Frey, Flavio Kapczinski, Taiane de Azevedo Cardoso

Summary: This study employed machine learning techniques to identify predictors of illicit substance abuse/dependence among a large community sample of young adults in Brazil. The strongest predictors included alcohol abuse/dependence, tobacco abuse/dependence, current major depressive episode, history of a lifetime manic episode, current suicide risk, and male sex. The findings indicate that machine learning techniques can accurately predict illicit substance abuse/dependence among young adults using sociodemographic/clinical characteristics.

JOURNAL OF PSYCHIATRIC RESEARCH (2023)

Add to Collection

Article Clinical Neurology

Arketamine as adjunctive therapy for treatment-resistant depression: A placebo-controlled pilot study

Gustavo C. Leal, Breno Souza-Marques, Rodrigo P. Mello, Igor D. Bandeira, Ana Teresa Caliman-Fontes, Beatriz A. Carneiro, Daniela Faria-Guimaraes, Livia N. F. Guerreiro-Costa, Ana Paula Jesus-Nunes, Samantha S. Silva, Daniel H. Lins-Silva, Mariana A. Fontes, Raiza Alves-Pereira, Vivian Cordeiro, Sidelcina Rugieri-Pacheco, Cassio Santos-Lima, Fernanda S. Correia-Melo, Flavia Vieira, Gerard Sanacora, Acioly L. T. Lacerda, Lucas C. Quarantini

Summary: This study aimed to explore the feasibility of using (R)-ketamine (arketamine) for treatment-resistant depression (TRD) and assess its efficacy and safety compared to placebo. The results showed that arketamine was not significantly different from placebo in treating depression. The findings highlight the importance of conducting further clinical trials.

JOURNAL OF AFFECTIVE DISORDERS (2023)

Add to Collection

Article Psychiatry

Triggers for acute mood episodes in bipolar disorder: A systematic review

Catarina Rodrigues Cordeiro, Beatriz Romao Corte-Real, Rodrigo Saraiva, Benicio N. Frey, Flavio Kapczinski, Taiane de Azevedo Cardoso

Summary: This systematic review aimed to identify triggers of acute mood episodes in bipolar disorder (BD). The review found that pharmacotherapy, particularly the use of antidepressants, was the trigger with the strongest evidence for manic/hypomanic relapse. Other identified triggers for mania included brain stimulation, energy drinks, acetyl-lcarnitine, St. John's wort, seasonal changes, hormonal changes, and viral infections. However, there is a lack of evidence regarding triggers for depressive relapses in BD, highlighting the need for further research in this area.

JOURNAL OF PSYCHIATRIC RESEARCH (2023)

Add to Collection

Article Health Care Sciences & Services

Taking modern psychiatry into the metaverse: Integrating augmented, virtual, and mixed reality technologies into psychiatric care

T. J. Ford, Derrick M. Buchanan, Azeezat Azeez, David A. Benrimoh, Irakli Kaloiani, Igor D. Bandeira, Saron Hunegnaw, Lucy Lan, Mia Gholmieh, Vivek Buch, Nolan R. Williams

Summary: The landscape of psychiatry is being influenced by new technologies, with the metaverse being one technology with potential applications. The metaverse is a virtual world accessed through AR/VR/MR, offering new possibilities and challenges. This article focuses on leveraging the metaverse in medical education, brain stimulation, and biofeedback, while also discussing ethical and data security concerns.

FRONTIERS IN DIGITAL HEALTH (2023)

Add to Collection

Review Clinical Neurology

Atypical antipsychotic-induced mania: A systematic review and meta-analysis

Beatriz Corte-Real, Rodrigo Saraiva, Catarina Rodrigues Cordeiro, Benicio N. Frey, Flavio Kapczinski, Taiane de Azevedo Cardoso

Summary: The study aimed to investigate whether atypical antipsychotics (AA) can induce mania in mood disorders. A systematic review and meta-analysis showed that AA-induced mania is rare and the use of AA is more effective in preventing the development of mania compared to placebo.

JOURNAL OF AFFECTIVE DISORDERS (2023)

Add to Collection

Article Psychiatry

Brain-derived neurotrophic factor serum levels following ketamine and esketamine intervention for treatment-resistant depression: secondary analysis from a randomized trial

Ana Teresa Caliman-Fontes, Gustavo C. Leal, Fernanda S. Correia-Melo, Camilla S. Paixao, Michelle S. Carvalho, Ana Paula Jesus-Nunes, Flavia Vieira, Guilherme Magnavita, Igor D. Bandeira, Rodrigo P. Mello, Graziele Beanes, Samantha S. Silva, Mariana Echegaray, Lucas P. Carvalho, Paulo Machado, Aline S. Sampaio, Taiane de A. Cardoso, Flavio Kapczinski, Acioly L. T. Lacerda, Lucas C. Quarantini

Summary: Evidence suggests that the influence of ketamine on BDNF may play a role in its rapid antidepressant action. However, this study found no significant impact of ketamine or esketamine on serum BDNF levels in treatment-resistant depression (TRD) patients. Both drugs showed similar therapeutic effects, and there was no association between BDNF levels and treatment response or severity of depressive symptoms.

TRENDS IN PSYCHIATRY AND PSYCHOTHERAPY (2023)

Add to Collection

Article Cell Biology

Systemic GDF11 attenuates depression-like phenotype in aged mice via stimulation of neuronal autophagy

Carine Moigneu, Soumia Abdellaoui, Mariana Ramos-Brossier, Bianca Pfaffenseller, Bianca Wollenhaupt-Aguiar, Taiane de Azevedo Cardoso, Aurelie Chiche, Nicolas Kuperwasser, Ricardo Azevedo da Silva, Fernanda Pedrotti Moreira, Han Li, Franck Oury, Flavio Kapczinski, Pierre-Marie Lledo, Lida Katsimpardi

Summary: Moigneu, Abdellaoui and colleagues discovered that GDF11 can alleviate depression symptoms and improve memory in aged mice by promoting neuronal autophagy and inhibiting mTOR activity. Low levels of GDF11 are associated with depression in human patients. This study provides insights into the mechanisms of GDF11 in the brain and suggests its potential as an antidepressant candidate and biomarker.

NATURE AGING (2023)

Add to Collection

Letter Psychiatry

Discussing clozapine adverse effects and monitoring strategies: a focus on ethnic diversity

Ana Teresa Caliman-Fontes, Gustavo C. Leal, Ary Gadelha, Lucas C. Quarantini

BRAZILIAN JOURNAL OF PSYCHIATRY (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.